Follicle stimulating hormone levels as a predictor of recovery of spermatogenesis following cancer therapy.
Infertility, both temporary and permanent, is a well-recognized complication of certain cancer treatments. The main objective of this study was to determine whether recovery of fertility in male patients, could be predicted by monitoring changes in serum follicle stimulating hormone (FSH) levels. Twenty male patients participated in the study. Sperm counts and serum FSH levels were measured before, during and after treatment. Azoospermia was universal in all 20 patients during the first year, with significantly raised FSH in almost all the patients. Reduction of FSH levels during the second year was frequently followed by recovery of spermatogenesis. Patients in whom the FSH did not fall during the second year were highly unlikely to regain fertility.
Kader
H A
HA
St Lukes Hospital, Guildford, Surrey, UK.
Rostom
A Y
AY
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007248:Infertility, Male / Q000139:chemically induced*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy; D011379:Prognosis; D013091:Spermatogenesis / Q000187:drug effects* / Q000528:radiation effects; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy
D005640:Follicle Stimulating Hormone